PKR is an interferon(IFN)-induced, serine-threonine protein kinase, which plays a crucial role in IFN's antiviral and antiproliferative actions. The three known activators of PKR are dsRNA, heparin, and PACT. PACT activates PKR by direct protein-protein interaction in response to cellular stress. The human TAR (trans-activating region)-binding protein (TRBP), which is very homologous to PACT, also interacts with PKR, leading to an inhibition of PKR activity. Since these two highly homologous proteins have opposite effects on PKR, we examined if they interact with PKR differently by assaying their interaction with various point mutants of PKR. Our results indicate that TRBP and PACT interact with PKR through the same residues, and no differences were identified in these two interactions. Domain swap experiments between PACT and TRBP indicated that the inhibitory effects of TRBP on PKR activity are mediated through its carboxyterminal residues, which contain TRBP's third dsRNA-binding motif.
Introduction
Interferons (IFNs) mediate their antiviral and antiproliferative actions by inducing a number of genes at the transcriptional level (Sen and Lengyel, 1992; Sen and Ransohoff, 1993) . PKR is an IFN-induced serine-threonine protein kinase which is one of the key molecules in IFN's cellular actions (Clemens and Elia, 1997; Meurs et al., 1990) . Although the impact of PKR activation has been best studied on antiviral pathways, PKR has also been shown to be involved in several cytokine and dsRNA-induced signaling pathways in the inflammatory response (Goh et al., 2000; Kumar et al., 1997; Williams, 1995 Williams, , 1999 . PKR activation leads to phosphorylation of its substrate, the ␣ subunit of the translation initiation factor 2 (eIF2␣), which results in a general block in protein synthesis (Colthurst et al., 1987; Samuel, 1993) . Although induced by IFNs, PKR's kinase activity stays latent until it is activated by binding to an activator. One of the best studied activators of PKR is the dsRNA, which serves a major role in activating PKR during viral infections (Hovanessian, 1989; Hovanessian et al., 1987; Katze, 1995 Katze, , 2002 . PKR has been shown to bind to dsRNAs as short as 11 bp long; however, a perfectly duplexed stretch of 50 bp is required for its activation (Manche et al., 1992) . dsRNAs that satisfy these requirements are not present in uninfected cells. PKR activation in response to a variety of stress signals other than virus infection is brought about by PACT, its only known protein activator (Ito et al., 1999; Patel and Sen, 1998a) . Treatment of mammalian cells with stress agents results in a rapid phosphorylation of PACT, its increased association with PKR, leading to PKR's activation, eIF2␣ phosphorylation, and subsequent apoptosis (Patel et al., 2000) . Thus, PACT overexpressing cells exhibit enhanced apoptosis in response to a variety of stress signals.
PACT's interaction with PKR occurs through the two conserved double-stranded RNA binding motifs (dsRBMs) present at the amino-terminus of PKR (Patel and Sen, 1998a) . These motifs are evolutionarily conserved and are present, often in multiple copies, in RNA-binding proteins from Escherichia coli to human (Fierro-Monti and Mathews, 2000; St Johnston et al., 1992) . Although these motifs were originally shown to be involved in binding to dsRNA, subsequent work showed their contribution to protein-protein interactions including dimerization of PKR (Cosentino et al., 1995; Ortega et al., 1996; Patel and Sen, 1998b; Patel et al., 1995 Patel et al., , 1996 Tian and Mathews, 2001) . Within these motifs, distinct basic residues on one side of an amphipathic helix are essential for interaction with dsRNA. Several hydrophobic residues on the other side of this amphipathic helix are essential for dimerization of PKR but dispensable for dsRNA binding, thereby indicating that the dsRNA binding and dimerization properties are independent of each other (Patel and Sen, 1998b) . Although several other proteins with these motifs also interact with PKR, it is unclear at present if dsRBMs in all other proteins also mediate protein-protein interactions in addition to their role in RNA binding. PACT contains three copies of dsRBM (M1, M2, and M3) and the two amino-terminal copies (motifs M1 and M2) mediate its interaction with PKR (Huang et al., 2002; Peters et al., 2001) . The third, carboxyterminal copy (Motif M3), lacks conservation of the crucial residues involved in dsRNA binding and therefore has no detectable dsRNA binding activity of its own. This motif plays an essential role in activation of PKR, and deletion mutants of PACT lacking this third motif can interact efficiently with PKR but are unable to activate its kinase activity (Huang et al., 2002; Peters et al., 2001) . Thus, the PKR interaction and activation motifs of PACT are distinct and nonoverlapping.
TRBP was originally identified and cloned as a gene encoding human immunodeficiency virus (HIV) trans-activating Region (TAR)-binding protein (Gatignol et al., 1991; Park et al., 1994) . TRBP belongs to the same family of RNA binding proteins and similar to PACT, possesses three copies of dsRBM (St Johnston et al., 1992) . TRBP and PACT share a high degree of homology and both these proteins are known to interact with PKR (Cosentino et al., 1995; Daher et al., 2001; Patel and Sen, 1998a ). TRBP's two aminoterminal dsRBMs interact in an dsRNA-independent manner with PKR's two dsRBMs, similar to the PACT-PKR interaction (Daher et al., 2001 ). Despite having a high degree of homology, these two proteins have opposite effects on PKR activation. PACT functions as an activator of PKR, whereas TRBP acts as an inhibitor (Daher et al., 2001; Park et al., 1994) . TRBP overexpression in NIH 3T3 cells has been shown to lead to malignant transformation due to the inhibition of PKR activity (Benkirane et al., 1997) . It is thus interesting that two very homologous proteins which interact with PKR through the same domains have opposite effects on PKR's activity. We reasoned that although the two proteins seem to interact through PKR's dsRBMs, they may be interacting through different residues within these domains, which could be studied by assaying interaction of different point mutants of PKR with both these proteins. Here, we report the results of these experiments using both in vitro coimmunoprecipitation and in vivo mammalian two-hybrid systems.
Results
PACT (PKR activator) and TRBP (PKR inhibitor) both belong to the same family of dsRNA binding proteins and are very homologous in their amino acid sequence (Fig. 1) . To determine if PACT and TRBP elicit opposite effects on PKR's kinase activity because they interact with PKR through different residues, we assayed their interaction with 16 point mutants of PKR. We have previously characterized these mutants with respect to their dsRNA binding and dimerization activities (Patel and Sen, 1998b; Patel et al., 1996) . Mutants such as A63E and L75E are defective in protein-protein interaction and show poor dimerization but have wild-type dsRNA binding affinities. On the other hand, mutants such as K60A show no detectable dsRNA binding activity but have significantly enhanced dimerization activity. We used the coimmunoprecipitation assay to determine the effect of 16 point mutations on PKR's ability to interact with these two proteins. As depicted in Fig. 2 , wtPKR protein could be coimmunoprecipitated with both flag-PACT ( Fig. 2A, lane 4) and flag-TRBP (Fig. 2B, lane 4) . The two mutants F41A and R18G also could be coimmunoprecipitated, but with reduced efficiency as compared to the wt PKR ( Figs. 2A and B , lanes 5 and 6). As a negative control, untagged PKR protein was translated alone, without any flag-tagged protein (lane 7). As seen in lane 8, no detectable PKR protein could be precipitated with flag antibody-agarose, thereby confirming the interaction between flag-PACT and flag-TRBP. Other mutants were assayed in the same manner, but due to space constraints, we have only shown representative data for two mutants in Figs. 2A and B. The amount of [
35 S]methionine counts in PKR and PACT in total and IP lanes was quantified by phosphorimager scanning and the percentage interaction was calculated with respect to the wild-type interaction, which was represented as 100%. As shown in Fig. 2C , mutants V72Y, F131A, and K150A showed no effect on the mutation on PACT and TRBP interactions. F131A and K150A have no dsRNA binding activity, but show strong interactions with PACT and TRBP. Mutants R18G, Q19L, Q110L, K154E, and A158D showed somewhat reduced interaction with PACT as well as TRBP. Mutants F41A, K60A, A63E, K64E, A67E, A68D, and L75E showed significant reduction in interaction with both PACT and TRBP, thereby indicating the importance of these residues in mediating their interactions. On the other hand, the mutant K61A showed significantly enhanced interaction with both PACT as well as TRBP. From these results, it can be concluded that PKR-PACT and PKR-TRBP interactions are likely to be mediated via the same residues within PKR's two conserved dsRBMs.
To confirm these in vitro observations, we also per-formed in vivo protein interaction assay using the mammalian two-hybrid system originally developed by Fields and Song (1989) . The two proteins, whose interaction is being tested, are expressed as fusion proteins in mammalian cells. One protein is fused to the DNA binding domain of the yeast GAL4 protein and the other is fused to the transactivation domain of the VP16 protein of herpes simplex virus. The two plasmids are cotransfected in cells along with the reporter plasmid in which the luciferase gene is under the control of GAL4 binding sites and the synthesis of luciferase is assayed by measuring its enzyme activity. In this system, if the two proteins interact, the interaction brings the VP16 activation domain in close proximity of the reporter gene promoter and induces transcription of luciferase in a quantitative manner. The amount of luciferase activity can be directly correlated to the strength of the interaction between the two proteins. We have previously used this system successfully to detect and characterize the PKR dimerization in mammalian cells (Patel and Sen, 1998b; Patel et al., 1996) . Here, we assayed the interaction between VP16-PKR and GAL4-PACT or GAL4-TRBP. As shown in Fig. 3A , both PACT and TRBP showed a strong interaction compared to the empty vector controls. The relative strengths of the interactions between mutant PKR and PACT (white bars) or TRBP (black bars) were similar to our results with in vitro coimmunoprecipitation assays. In addition, there were no differences observed between PACT and TRBP interactions with mutant PKR. Both proteins behaved similarly in this assay with respect to PKR interaction. However, distinct differences can be identified between PKR's interaction with itself (gray bars) and with PACT/TRBP. F41A, K60A, K64E, K150A, and K154E mutants showed enhanced PKR dimerization activity previously (Patel and Sen, 1998b; Patel et al., 1996) . However, these mutants showed significantly reduced interaction with PACT and TRBP. Similarly, K61A, which showed no significant effect on PKR dimerization (Patel et al., 1996) , showed an enhanced interaction with PACT and TRBP. Differences in expression levels of the interacting proteins can also lead to the differences in the reporter enzyme activity. To confirm that the interacting proteins were expressed at comparable levels in the transfected cells, we performed Western blot analyses with anti-VP16 and anti-GAL4 antibodies. As seen in Figs. 3A and B, all proteins were expressed at uniform levels, thereby confirming that the luciferase values obtained were a true result of the relative strengths of these interactions.
Our previous results have shown that the carboxy-terminal motif M3 of PACT (Fig. 4) serves as the activator of PKR's kinase activity, and the interaction between PACT and PKR is mainly mediated via the M1 and M2 motifs of PACT (Huang et al., 2002; Peters et al., 2001 ). In addition, we have also shown that a chimeric protein containing the M1 and M2 motifs of TRBP fused to the M3 motif of PACT can activate PKR, thereby strengthening the role of motif M3 in PKR activation (Huang et al., 2002) . These results suggested that the inhibitory actions of TRBP on PKR may be mediated via its M3 motif. We therefore created an expression construct encoding a chimeric protein (Fig. 4A) that consisted of the M1 and M2 motifs of PACT fused in-frame to the M3 motif of TRBP (P12T3). We confirmed that the chimeric construct encoded a protein of correct molecular weight and had corresponding parts of the two proteins by Western blot analysis (data not shown). We tested the ability of this protein to activate PKR in an in vivo translation inhibition assay (Huang et al., 2002; Patel and Sen, 1998a) . Transient overexpression of PACT in mammalian cells leads to PKR activation and eIF2␣ phosphorylation, which can be measured by assaying the expression of a cotransfected reporter gene such as luciferase. This in vivo translation repression assay has been used widely by us and others for PKR activation or inhibition ability of proteins in mammalian cells Kaufman and Murtha, 1987; Park et al., 1994; Patel et al., 1996; Peters et al., 2001 ). As shown in Fig. 4B , cotransfection of wtPKR reduced the luciferase activity significantly and cotransfection with TRBP showed enhanced activity. Cotransfection with a PACT expression construct and T12P3 also showed reduced luciferase activity as reported before, although this was not as pronounced as PKR effect. Cotransfection with the P12T3 expression construct showed an enhancement of luciferase activity. These results suggest that a substitution of M3 motif of PACT with the M3 motif of TRBP leads to an inhibitory effect on PKR activity. These results were further confirmed by assaying the effect of recombinant P12T3 protein on in vitro PKR activity assays. The purity of the recombinant P12T3 protein was assessed by SDS-PAGE (data not shown). As seen in Fig. 4C , addition of PACT could activate PKR activity (lane 4) but addition of P12T3 resulted in 35 S]methionine-labeled PACT (A) or TRBP (B) proteins were synthesized by cotranslation with untagged wtPKR or mutant PKR proteins using the T7 TNT system. Five microliters of the reticulocyte lysates were used for coimmunoprecipitation assay using antiflag antibody M2-agarose. The total lanes (lanes 1-3 and 7) represent 2 l of total proteins from the lysate and the IP lanes (lanes 4 -6, and 8) represent coimmunoprecipitated proteins remaining bound to beads after washing. The names of the PKR point mutants that were cotranslated with PACT/TRBP are indicated at the top of the lanes and the positions of the respective bands are indicated by arrows. The coimmunoprecipitated PKR bands are also indicated by arrows. Lane 7 represents the negative control where only PKR was translated, without any flag-tagged protein, and lane 8 shows the immunoprecipitation of this sample. (C) The coimmunoprecipitation gels were quantified by phosphorimager analysis. The radioactivity present in the bands was measured and the percentage interaction was calculated as 100 ϫ (radioactivity present in the coimmunoprecipitated PKR band/the radioactivity present in the PKR band in the total lane). In addition, this value was normalized to the amount of radioactivity present in the flag-PACT or flag-TRBP bands to correct for differences in translation/immunoprecipitation steps. The interaction between wtPKR and TRBP/PACT was taken as 100% and other interactions were normalized with respect to that. The open bars represent PACT and the black bars represent TRBP. The error bars represent the standard deviation from five independent experiments. a dose-dependent inhibition of PKR activity (lanes 2 and 3) . Thus, the PKR activation by PACT and inhibition by TRBP is mediated via their M3 motifs, and not because their interaction with PKR is mediated through different residues within PKR's dsRBMs.
Discussion
PKR, PACT, and TRBP belong to a family of RNAbinding proteins that share an evolutionarily conserved dsRBM (St Johnston et al., 1992) . Several proteins belonging to this family have been characterized from E. coli to human and many of them contain multiple copies of the conserved motif (Fierro-Monti and Mathews, 2000) . Despite being highly homologous, PACT and TRBP show opposite effects on PKR activity. PACT heterodimerizes with PKR in response to cellular stress and activates it (Ito et al., 1999; Patel et al., 2000; Peters et al., 2001 ). On the other hand, heterodimerization with TRBP results in inhibition of PKR activity (Daher et al., 2001; Park et al., 1994) . Both proteins interact with PKR through its dimerization Fig. 3 . In vivo PACT/TRBP interaction activities of PKR mutants in mammalian two-hybrid system. (A) COS-1 cells were transfected with a mixture four plasmids: 100 ng VP16 AD-DRBD (wt or point mutants) expression plasmids, 100 ng GAL4 DBD-PACT or GAL4 DBD-TRBP, 800 ng pG5LUC (reporter plasmid), and 2 ng of pRSV-␤-galactosidase (for normalization of transfection efficiency). Cells were harvested 24 hr after the transfection and assayed for luciferase and ␤-galactosidase activity. The luciferase values were normalized with the ␤-galactosidase values and the interaction between the wt proteins was taken as 100% interaction and all other interactions were calculated with respect to that. Gray bars represent interactions between PKR-PKR; white bars represent interactions between PKR and flag-PACT and black bars represent interactions between PKR and flag-TRBP. The different point mutants of PKR tested are indicated under the respective bars. (B) Western blot analysis. To ascertain that all the fusion proteins were expressed at comparable levels, 100 g of total protein from cell lysates was analyzed by Western blot analysis with an anti-VP16 activation domain antibody from the PKR-TRBP interaction set. (C) Western blot analysis. To ascertain that all the fusion proteins were expressed at comparable levels, 100 g of total protein from cell lysates was analyzed by Western blot analysis with an anti-GAL4 DNA binding domain antibody from the PKR-TRBP interaction set.
domain, which coincides with its dsRBM. Their interaction with PKR has been shown to be independent of PKR's dsRNA binding activity and point mutants of PKR that are defective in binding dsRNA show strong interactions with both PACT and TRBP (Patel et al., 1996 and Fig. 2) . PACT has three copies of the conserved dsRBM and its interaction with PKR is mediated by its two amino-terminal copies (Huang et al., 2002; Peters et al., 2001) . The third copy of the conserved motif is not involved in mediating the interaction. It also lacks certain conserved, basic residues that are crucial for dsRNA binding and is therefore devoid of any detectable dsRNA-binding activity. However, this third, carboxy-terminal domain is essential for activation of PKR and a deletion of this domain leads to a total loss of PKR activation (Huang et al., 2002; Peters et al., 2001) .
Here, we have investigated the effect of point mutants in PKR's dimerization/dsRBM on its interaction with PACT and TRBP. Our results indicate that PACT and TRBP interact with PKR through the same residues within the dimerization domain and that their opposite actions are mediated by the carboxy-terminal third conserved domains, which are also the most divergent. PACT and TRBP differ in their dsRNA-binding activities. The motifs M1 and M2 of PACT show strong interaction with dsRNA, whereas the motif M3 shows no detectable dsRNA binding. In the case of TRBP, the motifs M1 and M3 show no dsRNA binding and the dsRNA binding of TRBP is mainly mediated through its motif M2 (Daher et al., 2001 ). However, both M1 and M2 motifs of TRBP direct its heterodimerization with PKR (Daher et al., 2001) , thereby indicating that motif M2 can mediate interaction with PKR, despite its lack of dsRNA binding.
Although the point mutations affected the PACT-PKR and TRBP-PKR interactions in a similar manner, we did observe significant differences with respect to their effect on PKR-PKR interactions. Mutations such as F41A, K60A, K64E, K150A, and K154E did not affect the PKR-PKR interaction but were deleterious for PACT-PKR and TRB-P-PKR interactions. K61A mutation did not affect the PKR-PKR interaction but showed enhanced interaction with PACT and TRBP. Several mutations such as A63E, A67E, A68D, L75E, and A158D were deleterious to all three interactions. These results suggest that the interactions mediated by different dsRBM motifs may be dependent on different residues in the interacting partners. In this regard, PACT-PKR and TRBP-PKR interactions are mediated by similar residues in PKR's dsRBMs, but the PKR-PKR interaction occurs via an overlapping but different set of residues.
The domain swap experiments indicated that the PKR activation ability of PACT was lost when the carboxyterminal motif M3 of PACT was substituted with the corresponding motif M3 of TRBP (Huang et al., 2002) . Similarly, the PKR-inhibitory activity of TRBP was lost when motif M3 of TRBP was substituted with the corresponding motif M3 from PACT. These results indicate that TRBP and Twenty-four hours after the transfection, the cells were treated with 100 U/ml of IFN␤ for 24 h and luciferase activity was measured in the cell extracts and normalized to the total protein in the extract. All expression constructs were in pCB6 ϩ . "Vector" indicates empty vector (pCB6 ϩ ) control. Each sample was assayed in triplicate and the bars represent an average of six samples from two separate experiments. The error bars indicate standard deviation. (C) P12T3 protein inhibits PKR activity in a dose-dependent manner. Effect of purified recombinant P12T3 protein added to PKR kinase activity assays was studied. Lane 1: no activator added; lane 2-3: 0.25, and 0.5 pmol of pure recombinant P12T3 protein added, respectively; lane 4: 0.116 pmol of pure recombinant PACT. The positions of phosphorylated PKR and eIF2␣ are indicated by arrows.
PACT's opposing actions on PKR activity mainly result from differences in their carboxy-terminal motif M3 and the two proteins interact with PKR through the same residues within PKR's dsRBMs. These results raise an interesting question about the ability of an dsRBM to activate PKR. The third dsRBMs of both PACT and TRBP do not exhibit any dsRNA binding activity and also are the least homologous among the three dsRBMs of PACT and TRBP. In addition to the sequence differences, the spacing between the M2 and M3 domains is different in PACT and TRBP. TRBP has a significantly longer spacer between M2 and M3. We know that the spacer region between M2 and M3 of PACT is not essential to PKR activation, since the recombinant M3 domain by itself can activate PKR in vitro and interacts directly albeit transiently with PKR's catalytic domain (Huang et al., 2002) . The recombinant M3 domain of TRBP showed no effect on PKR activity in vitro (data not shown), thereby indicating that unlike PACT's M3 domain, it lacks the PKR interaction and activation ability. Future experiments with reduced spacing between M3 domain of TRBP in the P12T3 construct and additional point mutants within M3 domains of PACT and TRBP can indicate the importance of spacing and/or crucial residues essential for PKR activation.
The dsRBMs have been found in proteins from several diverse sources, such as bacteria, lower and higher eukaryotes, and viruses (Fierro-Monti and Mathews, 2000; St Johnston et al., 1992) . Most of these dsRNA binding proteins contain multiple dsRBMs. Several proteins belonging to this class have been described as PKR-interacting proteins including PACT, TRBP, NF90 (Langland et al., 1999; Parker et al., 2001; Patel et al., 1999) , and p74 (Coolidge and Patton, 2000) . However, the cellular functions of many other proteins in this family remain unknown. Since the conserved motif directs both homo-and heterodimerization between this class of proteins, it remains to be examined if such interactions can be regulatory as in the case of TRBP-PKR and PACT-PKR.
Materials and methods

In vitro protein-protein interaction assays
35 S-labeled PKR and flag epitope-tagged PACT protein or TRBP protein were cotranslated using the TNT T7 coupled reticulocyte system from Promega. Five microliters of the in vitro translated 35 S-labeled proteins was incubated with 20 l of anti-flag mAb-agarose (Sigma) in 200 l of IP buffer [20 mM Tris-HCl pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 100 U/ml aprotinin, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 20% glycerol, 1% Triton X-100] at 4°C for 30 min on a rotating wheel. The beads were washed in 500 l of IP buffer four times and the washed beads were then boiled in 2ϫ Laemmli buffer (150 mM Tris-HCl pH 6.8, 5% SDS, 5% ␤-mercaptoethanol, 20% glycerol) for 2 min and eluted proteins were analyzed by SDS-PAGE on a 12% gel. The dried gels were analyzed by phosphorimager analysis. The percentage interaction was calculated based on input counts and immunoprecipitated counts of the PKR bands. The amounts were normalized not only to the input counts, but also to the total amount of flag-PACT or flag-TRBP that was immunoprecipitated. The interaction between the wtPKR and TRBP/ PACT was taken as 100% and all other interactions were represented with respect to that.
In vivo protein-protein interaction assays
The in vivo interaction between the various point mutants of PKR and PACT or TRBP was assayed using the mammalian two-hybrid system as described before (Patel and Sen, 1998a,b; Patel et al., 1995 Patel et al., , 1996 . The DRBD portions of the various point mutants were amplified previously by PCR and subcloned into pVP16AASV19N (Takacs et al., 1993) . These constructs express the DRBDs as a VP16 activation domain (AD) fusion protein and are tested for interaction with a GAL4 DNA-binding domain (DBD) fusion of PACT or TRBP. COS-1 cells were transfected with 200 ng of each of the four (two test plasmids encoding proteins to be tested for interaction, the reporter plasmid pG5Luc, and plasmid pRSV-␤-galactosidase to normalize transfection efficiency) plasmid DNAs by the Lipofectamine (Invitrogen) procedure. Cells were harvested 48 h after transfection and assayed for luciferase activity after normalization for transfection efficiency by measuring ␤-galactosidase activity.
Construction of domain swap mutants P12T3 and T12P3
The construction of P12T3 has been described before (Huang et al., 2002) . P12T3 construct was created to encode the amino acids 1-196 of PACT fused to the amino acids 200 -345 of TRBP. The resulting chimeric P12T3 protein is 342 amino acids long. The fusion construct was created by PCR amplification of the relevant TRBP region. The EcoRI site in PACT coding region was used to fuse the PCR product in-frame to PACT by designing the EcoRI site within the upstream PCR primer. The resulting chimeric cDNA was confirmed by sequencing and subcloned into eukaryotic expression vector pCB6 ϩ and a flag epitope tag was introduced at the amino-terminal end of the protein to monitor expression. The chimeric cDNA was also subcloned into prokaryotic expression vector pET15b (Novagen). The recombinant P12T3 protein was expressed and purified from E. coli as described before (Huang et al., 2002) .
Translation inhibition assays
The effects of PACT and TRBP and their mutants were tested using the translation inhibition assay as described before. In this assay, the effect of cotransfection with an effector plasmid is tested on translation of a reporter such as luciferase. MEF cells were transfected in six-well plates in triplicate with 800 ng of pGL2C reporter plasmid and 200 ng of effector plasmid (expression constructs of flag-PACT, flag-TRBP, flag-P12T3, and flag-T12P3) DNAs using the Lipofectamine reagent. At 24 h after transfection, the cells were treated with 100 U/ml of IFN-␤. Cells were harvested 48 h after transfection and assayed for luciferase activity.
PKR activity assay
PKR activity assays were performed as described before (Patel et al., 2000 Patel and Sen, 1998a ) using anti-PKR monoclonal antibody (Ribogene, 71/10 monoclonal). HeLa M cells were maintained in DMEM with 10% FCS. The cells were harvested when they were at 70% confluency. Cells were washed in ice-cold phosphate-buffered saline (PBS) and packed by centrifugation at 600g for 5 min. They were lysed by addition of an equal volume of lysis buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl 2 , 50 mM KCl, 400 mM NaCl, 2 mM DTT, 1% Triton X-100, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol). The lysates were centrifuged at 10,000g for 5 min and the supernatants were assayed for PKR activity. A 100-g aliquot of total protein was immunoprecipitated using PKR monoclonal antibody (71/10) in the high salt buffer (20 mM Tris-HCl pH 7.5, 50 mM KCl, 400 mM NaCl, 1 mM EDTA, 1 mM DTT, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol, 1% Triton X-100) at 4°C for 30 min on a rotating wheel. Then 10 l of protein A-Sepharose slurry was added and incubation was carried out for a further 1 h. The protein A-Sepharose beads were washed in 500 l of high salt buffer four times and twice in activity buffer (20 mM Tris-HCl pH 7.5, 50 mM KCl, 2 mM MgCl 2 , 2mM MnCl 2 , 100 U/ml aprotinin, 0.1 mM PMSF, 5% glycerol). PKR assay was performed with PKR still attached to the beads in activity buffer containing 250 ng of purified eIF-2 (kindly provided by Dr. William Merrick, Case Western Reserve University), 0.1 mM ATP, and 1 Ci of [␥-32 P]ATP at 30°C for 10 min poly(I)-poly(C) (0.1 g/ml) or 0.116 pmol of pure PACT protein was used as the standard activator for the enzyme. Purified P12T3 in amounts 0.115 and 115 pmol were added to test its effect on PKR activity. Labeled proteins were analyzed by SDS-PAGE on a 12% gel followed by autoradiography.
